EC
RETA

EcoR1 Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

EcoR1 Capital’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-38,467
Closed -$967K – 76
2022
Q3 		$967K Sell
38,467
-1,937,144
-98% -$53.7M 0.03% 68
2022
Q2 		$60M Hold
1,975,611
– – 2.07% 15
2022
Q1 		$64.7M Buy
+1,975,611
New +$58.6M 2.02% 16

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

EcoR1 Capital's RETA Position: Q4 2022 in Review

EcoR1 Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 38,467 shares — an estimated $967K sold.

EcoR1 Capital first reported a position in RETA in Q1 2022 and held it in 3 quarters. The position peaked at $64.7M in Q1 2022. 167 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

  • EcoR1 Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
  • EcoR1 Capital sold 38,467 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $967K.
  • EcoR1 Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 3 quarters.
  • EcoR1 Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $64.7M in Q1 2022.
  • 167 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on EcoR1 Capital's 13F filing for Q4 2022, filed 14 Feb 2023.